ImmunoPrecise Finanical Report

ImmunoPrecise Antibodies Reports Q1 2018 Results

ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business. Increases Operational Efficiency and Expands Capacity to Scale Quickly September 29, 2017 – Victoria, B[...]

October 1, 2017
ImmunoPrecise Increased Financing

ImmunoPrecise Increases Financing to $5.25 Million

Victoria, British Columbia, Canada, August 2, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express [...]

August 2, 2017